skip to Main Content

Dr. O’Reilly on the NEOLAP Study in Locally Advanced Pancreatic Cancer

Dr. O’Reilly on the NEOLAP Study in Locally Advanced Pancreatic Cancer
Eileen O’Reilly, MD, associate director for clinical research and medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the phase II NEOLAP study which showed that more patients with locally advanced pancreatic cancer were able to undergo surgical resection following induction chemotherapy with gemcitabine and nab-paclitaxel (Abraxane) or sequential FOLFIRINOX. 

Watch here . . .


Back To Top